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ABSTRACT
Background: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe adverse
drug reactions with high mortality.
Methods: To present the current clinical characteristics and treatment of SJS and TEN in Japan, we retro-
spectively analyzed reports of SJS and TEN published in medical journals from 2000 to 2006.
Results: Fifty-two cases of SJS (19 males and 33 females; mean age, 45.2 years) and 65 cases of TEN (31
males and 34 females; mean age, 45.7 years) were reported. Thirty-six cases of SJS (69.2%) and all cases of
TEN were caused by drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and anticon-
vulsant drugs. Hepatitis was the most common organ involvement in both SJS and TEN. Renal dysfunction and
respiratory disorders were also involved in some cases. The major complication was sepsis, but in only 1.9% of
SJS and 10.8% of TEN. Most cases were treated systemically with corticosteroids, and 42 cases (80.8%) of
SJS and 39 cases (60.0%) of TEN were treated with corticosteroids alone. Plasmapheresis andor immuno-
globulin therapy was combined with corticosteroid therapy in some cases. The mortality rates for patients with
SJS and TEN were 1.9% and 6.2%, respectively. The mortality in TEN decreased remarkably from 21.6% (58
269) during the previous 17 years (1981 to 1997).
Conclusions: Improvement of treatment may be one of the reasons for the decrease in mortalities of both
SJS and TEN.
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INTRODUCTION
Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN) are potentially fatal disorders, char-
acterized by high fever, wide-spread blistering exan-
thema of macules and atypical target-like lesions, ac-
companied by mucosal involvement.1-3 In SJS, detach-
ment of the epidermis is less than 10% of the body
surface area; the detachment is wider in TEN.3 In ad-
dition to the severe skin symptoms, both diseases are
often accompanied by complications in numerous or-
gans, such as the liver, kidney, and lung. Although
many factors have been proposed as causes of these
diseases, including adverse drug reactions, malignant
disorders, graft-versus-host disease and infections by
microorganisms such as viruses and Mycoplasma
pneumoniae, hypersensitivity to medications accounts
for most of the cases.4 Some investigators have pro-
posed that SJS and TEN are variations of the same
disease expressed with different severity,5 but there
is still strong disagreement regarding this concept.
However, the clinical manifestations and the pa-
thologic tests support the concept and show that SJS
and TEN differ from erythema multiforme, which
shows acrally distributed typical target or raised ede-
matous papules with or without mucosal involvement,
caused mainly by herpes simplex virus.6 The patho-
genesis of SJS and TEN remains to be elucidated but
apoptotic mechanisms, including involvement of cyto-
toxic T cells, tumor necrosis factor (TNF)-α, and Fas,
Fas ligand (FasL) interaction, are considered to be
relevant to these diseases.7-10
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Fig. 1 Age of Patients with SJS and TEN
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The reported mortality varies from 3% to 10% for
SJS and from 20% to 40% for TEN.11,12 Several treat-
ments have been reported to be beneficial but there
are no clear indications for the optimal treatment.
Systemic administration of corticosteroids is still con-
troversial in many countries,13 but this form of treat-
ment has become the mainstream of treatment in Ja-
pan. High-dose immunoglobulin therapy10,14-16 and
plasma apheresis17-19 are also considered effective in
some reports.
The aim of this study is to present the current clini-
cal characteristics and treatments of SJS and TEN in
Japan. We retrospectively analyzed reports of SJS and
TEN published in medical journals from 2000 to 2006.
METHODS
We collected reports on SJS and TEN in Japan, which
were published in medical journals between January
2000 and December 2006, using the Japana Centra
Revuo Medicina. Clinical reports were selected when
they contained enough information to make a cred-
ible diagnosis. For SJS, symptoms should include
acute conditions characterized by mucous membrane
erosions and skin lesions (described as macules,
atypical target-like lesions, bulla, erosions) with less
than 10% of maximum detachment of the skin surface
area; and for TEN the symptoms should include
more than 10% of maximum skin detachment in addi-
tion to the symptoms above. Therefore, SJS without
description of mucous involvement and TEN with
less than 10% of maximum skin detachment were ex-
cluded from this study, even if they were reported as
SJS or TEN. Cases reported as overlap of SJSTEN
were included in TEN.
The following data were collected: Demographic
information (age, sex), relevant past medical history,
antecedent use of medications, time between the first
causative drug intake and the onset of symptoms,
presence and extent of mucous membrane involve-
ment, laboratory data, treatment including corti-
costeroid therapy, high-dose immunoglobulin ther-
apy and plasmapheresis, complications and mortality.
The reference numbers of the items analyzed often
differed from case to case because they were speci-
fied differently in each report.
RESULTS
AGE AND SEX (Fig. 1)
Fifty two cases of SJS and 65 cases of TEN were ana-
lyzed in this study. In patients with SJS, comprising
19 males and 33 females, the ages were between 2
and 89 years (mean, 45.2 years). In patients with
TEN, comprising 31 males and 34 females, the ages
were between 1 and 88 years (mean, 45.7 years).
ETIOLOGY
In SJS, 36 cases (69.2%) were considered to be
caused by drugs, and five cases (10.4%) were sus-
pected to be caused by Mycoplasma pneumoniae, or
Mycoplasma pneumoniae andor drugs. The causes of
the other cases were not determined. In contrast, all
TEN cases had received drugs and were suspected to
be caused mainly by drugs. In both SJS and TEN, an-
tibiotics, anticonvulsants, and nonsteroidal anti-
inflammatory drugs (NSAIDs) and cold medicines
were the major causative drugs (Table 1).
SJS and TEN in Japan from 2000 to 2006
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Fig. 2 Time Between the First Causative Drug Intake and 
Onset of Symptoms
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Table 1 Causes of SJS and TEN
Number of cases
TENSJS
12 8Antibiotics
 2 1Penicilins
 5 6Cephems
 2 0Pyridone carboxylic acid
 1 0Sulfamethoxazole・trimeathoprim
 1 0Tetracycline
 1 1Polypeptides (vancomycin)
18 4NSAIDs † and cold medicine
12 3NSAIDs
 6 1Cold medicine
1110Anticonvulsants
 3 2Antipodagric (Alopurinol)
 0 2Antitussive
 0 2Anti-arhythmics (Mexiletine Hydrochloride)
 0 2Protease (serapeptase)
 1 1Contrast medium
  10§  7 ‡Others
1710 Not determined
7248Total
†NSAIDs; nonsteroidal anti inflammartory drugs
‡Include each case of; Peplomycin, glibenclamide, azathio-
prine, spironolactone, dihydrocodeine phosphate, mizoribine, 
acetazolamide
§ Include each case of; Cyanamide, amelaxanox, D-penicil-
lamin, imatinib mesylate, digestive enzymes, omeprazole, lyso-
zyme chloride, haloperidol, bromelain, bucilamine
Cephalosporins were the most frequent causative
drugs among antibiotics (10 cases in SJS and TEN)
and carbamazepine was the most frequent among an-
ticonvulsants (8 cases in SJS and TEN). Many other
kinds of drugs were also presumed to be the causes
in SJS and TEN, although the frequencies of these
cases were much lower than those mentioned above.
INTERVAL BETWEEN THE FIRST DRUG INTAKE
AND ONSET OF SYMPTOMS
The intervals between the first drug intake and the
onset of symptoms in 34 cases of SJS and 35 cases of
TEN are shown in Figure 2. More than half (67.6% of
SJS, 80.0% of TEN) of the patients developed symp-
toms within 2 weeks. Due to the fact that the symp-
toms appeared within 3 days in 18 cases (51.4%) of
TEN and in 9 cases (26.5%) of SJS, TEN thus seemed
to develop earlier than SJS.
MAXIMUM SKIN DETACHMENT IN TEN
The maximum skin detachment was specified in 44
cases of TEN. The range was 10% to 100% and the
mean was 49.6 %. Eleven cases showed 70% or more
detachment of the body surface area and 6 of these
showed expansion of the skin detachment even after
starting steroid therapy.
ORGAN INVOLVEMENT AND COMPLICATIONS
Many patients showed organ involvement and other
complications (Table 2). In both SJS and TEN, hepati-
tis was the most common complication. Twenty four
cases (46.2%) of SJS and 41 cases (63.1%) of TEN had
hepatitis. In 2 cases of SJS, alanine aminotransferase
(ALT) was elevated more than 1,000 IUml, but no
case of TEN showed such a conspicuous elevation of
ALT. This might suggest that SJS could cause more
severe hepatitis than TEN.
Respiratory disorders were shown in 11 cases
(21.2%) of SJS and 19 cases (29.2%) of TEN. They in-
cluded mucous membrane damage of trachea or
bronchus, bronchiolitis obliterans, pneumonia, respi-
ratory failure, subcutaneous emphysema, mediastinal
emphysema and others.
Five cases (9.6%) of SJS and 18 cases (27.7%) of
TEN showed renal dysfunction. Haemodialysis was
performed in one case of SJS and 3 cases of TEN. En-
cephalopathy, gastro-intestinal disorder and myo-
carditis were also reported in both SJS and TEN. Sep-
sis was more frequent in TEN than in SJS.
Eleven cases of SJS and 9 cases of TEN developed
late sequelae ophthalmic disorders, skin disorders,
respiratory disorders, and hepatitis. In SJS, 8 cases
developed ophthalmic symptoms such as corneal ul-
ceration, adhesions of the eye ball, dry eye and other
symptoms. One of these cases underwent an amnion
transplantation. On the other hand, fewer TEN cases
(6 cases) developed ophthalmic symptoms, and no
case needed cornea grafting.
TREATMENT
Major systemic treatments adopted in addition to sup-
portive care were classified into systemic administra-
tion of corticosteroids, high-dose immunoglobulin
therapy, and plasmapheresis. The treatments per-
formed are shown in Table 3. Only a few cases (4
cases of SJS and 2 cases of TEN) were treated with-
Yamane Y et al.
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Table 2 Organ Involvement and Complications in Patients with SJS and TEN
Number of cases (%)
TotalTENSJS
65 (55.6％)41 (63.1%)24 (46.2%)Hepatitis
 6 6 1T-bil ＞ 2 mg/dl
 8 5 3ALT † Not described
2620 6100 IU/l＞
241311500 IU/l＞, ≧ 100 IU/l
 5 3 21000 IU/l＞, ≧ 500 IU/l
 2 0 2＞ 1000 IU/l
23 (19.7％)18 (27.7%) 5 ( 9.6%)Renal dysfunction ‡
 4  3  1Haemodialysis
30 (25.6％)19 (29.2%)11 (21.2%)Respiratory disorder
13 (11.1％) 8 (12.3%) 5 ( 9.6%)Encephalopathy
14 (12.0％) 9 (13.8%) 5 ( 9.6%)Gastro-intestinal disorder
 2 ( 1.7％) 1 ( 1.5%) 1 ( 1.9%)Myocarditis
 8 ( 6.8％) 7 (10.8%) 1 ( 1.9%)Sepsis
 2 ( 1.7％) 1 ( 1.5%) 1 ( 1.9%)DIC §
†ALT; alanine aminotransferase
‡Cr ≧ 2 and/or Albuminuria and/or enforced Haemodialysis
 § DIC; disseminated intravenous coagulation
Table 3 Treatment for SJS and TEN
Number of cases
TENSJS
   2 (1)  4 No corticosteroids
3942Steroid therapy
 1 0 PSL † equiv PSL: ＜ 10
 0 2  PSL: 10―29
 811  PSL: 30―59
 8 9  PSL: ≧ 60
 3 4  not described
 8 7 mPSL ‡ 1 g/day×3 days
10  7 (1) mPSL 125―600 mg/day×3 days
 1 2 pulse dose not described
  12 (2) 6Steroid and immunoglobulin therapy
   4 (1) 0 High dose immunoglobulin (400 mg/kg/day)
   8 (1) 0Steroid therapy and plasmapheresis
  4  0Steroid and immunoglobulin therapy and plasmapheresis
  2  0 High dose immunoglobulin (400 mg/kg/day)
65 cases (4)52 cases (1)Total
† PSL; prednisolone
‡m PSL; methylprednisolone
( ): deceased cases
out corticosteroids. Forty-two (80.8%) cases of SJS
and 39 cases (60.0%) of TEN were treated with corti-
costeroids alone. Of these, 16 cases (30.8%) of SJS
and 19 cases (29.2%) of TEN were treated with ster-
oid pulse therapy (methylprednisolone (mPSL) 125～
1000 mgday for 3 days).
A combination of plasmapheresis and corticoster-
oid therapy without immunoglobulin was chosen in 8
cases of TEN. A combination of high-dose immuno-
globulin therapy and corticosteroid therapy was per-
formed in 4 cases of TEN. Two cases were treated
with corticosteroid, high-dose immunoglobulin and
SJS and TEN in Japan from 2000 to 2006
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Table 4 Mortality for SJS and TEN
Time to 
death †Treatments
Severe
complications
Maximum skin
detachment (%)
Causative
drugs
Case No./
age/sex
SJS
31 daysmPSL 250 mg/day×3 daysMRSA¶ sepsis
Hemophagocytosis
DIC∥
 8%Cefcapene
pivoxil?
NSAIDs#?
1 76/M
TEN
20 daysNo Corticosteroids?
Immunoglobulin?
Septic shock70%Piperacilin2 74/F
62 daysmPSL ‡1000 mg/day×7 days
(3 days ＋ 4 days), 
immunoglobulin
2.5 g×5 days
Sepsis, DIC
Intestinal bleeding
Respiratory disorder
＞ 90%  Alopurinol?3 72/F
73 daysmPSL 500 mg/day×3 days,
PA § 6 days
Septic shock
Multiorgan failure
90%NSAIDs4 53/F
24 daysmPSL 125 mg/day×3 days,
immunoglobulin
5 g×4 days (0.4 g/kg/day)
Respiratory disorder＞ 90%  Cefditren
pivoxil?
Acetoaminofen?
5 3/F
†Time between the onset of eruption and death
‡mPSL; methylprednisolone
 § PA; plasmapheresis
 ¶ MRSA; Methicilin-resistant staphylococcus aureus
 # NSAIDs; nonsteroidal anti inflammartory drugs
∥DIC; disseminated intravenous coagulation
plasmapheresis. In most cases, plasmapheresis was
performed using double filtration methods, and hu-
man immunoglobulin was administered as high-dose
therapy at a dose of 400 mgkg of body weight per
day for 3 days. These combination therapies were
chosen for patients in whom corticosteroid therapy
alone was not effective enough or when rapidly pro-
gressing symptoms were observed.
MORBIDITY AND MORTALITY
One patient with SJS (mortality rate, 1.9%) and 4 pa-
tients with TEN (mortality rate, 6.2%) died. A sum-
mary of the deceased cases is shown in Table 4. The
deceased SJS case was a 76 year-old man. He devel-
oped hemophagocytotic syndrome, MRSA pneumo-
nia and MRSA sepsis, and died 33 days after onset of
the illness.
As for TEN, all deceased cases were females. Their
ages varied from 3 years to 74 years, with a mean age
of 50.5 years. The skin detachment was 70% or more
of the body surface area. Except for one case, mPSL
was administered, and plasmapheresis was also per-
formed in one of them. Three cases developed sepsis,
and it appeared that control of the infections affected
the outcome of the treatment.
DISCUSSION
SJS and TEN are rare but serious disorders with sig-
nificant mortality. The pathogenesis is not fully eluci-
dated, although there have been recent develop-
ments in the understanding of the apoptotic pathways
of keratinocytes and in the immunological changes
that are related to adverse drug reactions in these dis-
eases. There is no definite specific treatment for SJS
or TEN, and establishment of adequate and more ef-
fective therapy is needed.
To clarify the current manifestations and manage-
ment of these diseases, we reviewed the clinical char-
acteristics and treatments of patients with SJS and
TEN that were reported in the literature from 2000 to
2006.
The ages of patients with SJS and TEN ranged
from infants to the elderly. The mean age was ap-
proximately 45 years in both diseases, which is as
high as those reported from other countries.20 The
major causative drugs were antibiotics, anticonvul-
sants, and NSAIDs and cold medicines. The predomi-
nance of these drugs in causing the diseases is un-
changed as compared with a study of 269 cases of SJS
and 287 cases of TEN, which were reported from
1981 to 1997 in Japan.21
In addition to the severe skin symptoms, the pa-
tients often had complications involving other organs
such as the liver, kidneys, lungs, and gastro-intestinal
tract. In addition to multi-organ involvement, another
major problem in the clinical course was secondary
infections, especially sepsis.
The mortality of both SJS and TEN decreased as
compared with the previous data of 1981―1997 (SJS,
from 6.3% to 1.9%; TEN, from 21.6% to 6.2%),21 even
though many patients developed organ involvement
and, in TEN, extensive skin detachment. These dif-
ferences might depend on differences in the numbers
of analyzed cases, but it could also be due to the cur-
Yamane Y et al.
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rent improvement of treatment for these diseases.
The use of corticosteroids is based on the idea that
corticosteroids can effectively suppress an excessive
immune response. However, their use is still contro-
versial. In 1983, Kim et al. suggested that treatment
with glucocorticoids in SJS and TEN is associated
with increased morbidity and mortality mainly due to
secondary infections.22 However, one should be
aware that the administration of steroids to patients in
their report often was delayed relative to disease on-
set and usually given in moderate doses and with pro-
longed duration. In many studies after the 1980s, the
authors stated that corticosteroids not only enhanced
the risk of sepsis23,24 but also delayed epithelializa-
tion. In contrast, in 2000, Tripathi et al. reviewed 67
patients with SJS, and found that 66 of these patients
recovered with steroid therapy (1 died due to causes
unrelated to steroid therapy).25 These authors recom-
mended the prompt use of high-dose systemic corti-
costeroids for a relatively brief period for the treat-
ment of SJS. Corticosteroids have also been recom-
mended for TEN by other authors.26-28 In our study,
corticosteroids were administered in most of the pa-
tients, and many of these patients were treated with
steroid pulse therapy. This might be one of the rea-
sons why the mortality of both SJS and TEN de-
creased during these years, because steroid pulse
therapy had been rarely chosen for the treatment of
SJS and TEN before 2000.
In addition to steroid therapy, plasmapheresis and
high-dose immunoglobulin therapy were performed
in some patients with TEN. Insufficient improvement
of the symptoms with steroid therapy seems to be a
big factor in choosing additional treatments. The skin
lesions and general conditions were aggravated even
after starting the steroid therapy in these patients.
Plasmapheresis has been reported to be effective
in several studies of TEN after the middle of the
1980s.18,19 The mechanism underlying the effective-
ness remains speculative but most likely involves re-
moval of drug and drug metabolites, antibodies, and
chemical mediators. In Japan, some patients with
TEN were treated with plasmapheresis after 1988.
However, the optimal method of use and the relevant
effects have not yet been established. In this study,
only one patient died among 8 patients treated with
plasmapheresis and steroids.
The effect of intravenous high-dose immunoglobu-
lin therapy has been investigated by several
groups14-16 after Viard et al.10 published a study of pa-
tients with acute TEN in 1998. The mechanisms are
suspected to involve inhibition of Fas-mediated
keratinocyte death by naturally occurring Fas-
blocking antibodies in the administered immuno-
globulin and inhibition of inflammatory cytokines.
French et al. summarized the clinical studies re-
ported and suggested that the use of more than 2 g
kg of body weight of intravenous immunoglobulin is
beneficial in reducing the mortality associated with
TEN.14 In our study, less immunoglobulin (0.4 gkg
days for 3 days) was administered together with ster-
oid in 4 patients, and one of these patients died. Two
seriously ill patients underwent plasmapheresis and
received high-dose immunoglobulin therapy in com-
bination with steroid therapy, with no mortality.
These results suggest that the combination of these 3
treatments might be useful in seriously affected pa-
tients. More experience is needed to confirm the ef-
fect.
Five deceased cases were reported in the seven
years of our review. Four of the cases developed sep-
sis and three of these cases were treated with steroid
pulse therapy. According to our previous study, multi-
organ involvement and DIC was observed in many
deceased patients without sepsis who had been
treated only with a moderate dose of corticoster-
oids.21 Therefore, the remarkable improvement of
the mortality of both SJS and TEN suggests that the
use of steroid pulse therapy decreased the risk of the
fetal organ involvement, although there is a possibil-
ity that the use of steroid pulse therapy enhanced the
risk of infection.
Our review of the literature leads us to conclude
that steroid therapy with high-dose corticosteroids is
effective in SJS and that treatment combinations may
be useful in extensive and aggravated TEN, although
the selection of cases was biased because we were
limited to evaluating published cases.
In France and Germany, a registry of patients with
SJS and TEN has already been established since the
mid-1990s, and a large-scale epidemiologic study is
ongoing. A similar registry system is needed in Japan
to evaluate the efficacy of therapies. In addition, such
a system might be useful for analysis of genetic mark-
ers.
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